SIDBI Venture Capital invests in OmniBRx Biotechnologies Private Limited

OmniBRx Biotechnologies Private Limited receives investment from SIDBI Venture Capital

New Delhi (India), March 17:  OmniBRx, a bioprocess engineering company, announced a Series a equity raise of INR 30 crore from SIDBI Venture Capital Limited.

Commenting on the occasion, Mr. Ravindra Patel, founder and CEO of OmniBRx Biotechnologies, said, “We are thankful to the team at SVCL for believing in our vision and backing us on our expansion plans”. He further added that “Scalable and Efficient bioprocessing technologies, specifically the Single-use bioreactor platforms, are in high demand worldwide for the production of vaccines and other biologicals. Innovation-based technology solutions from OmniBRx have the potential to meet these exponentially growing market demands of biologics and vaccines.

The CellBRx Single-use Bioreactors from OmniBRx are the world’s largest and most efficient vaccine manufacturing platform for large-scale vaccines and viral vector Production. OmniBRx is also the creator of the world’s first integrated seed train development platforms in close-loop sequentially programmed bioreactor systems,” Ravindra added.

With an infusion of series-A funds, OmniBRx is all set to expand its business in the overseas market. The company would also invest in adding to its capacity and building best-in-class manufacturing facilities to augment its production capabilities and meet growing market demands.

Sajit Kumar. Sr. VP at SIDBI Venture Capital Limited quoted, “We are happy to partner with OmniBRx. We believe that their focus and deep domain knowledge will help them to penetrate the global markets. This is our third investment out of “Ubharte Sitaare Fund”, a fund for MSME’s focused on scaling up in the export markets. Wishing them all the best”.

Delhi-based Indus Capital, a boutique investment bank founded by Mr. Santosh Patra, was the exclusive financial advisor to OmniBRx for this transaction.

About OmniBRx, it is an Ahmedabad-based Bioprocess engineering company focused on the design and development of novel single-use bioreactors (SUBs) for cell culture-based bioprocessing applications, i.e. Vaccines, Gene therapies, and biologics production. The Company was incorporated in 2016 and successfully launched its innovative products like CellBRx and MiniBRx single-use Bioreactor platforms.

About SIDBI Ventures, the company incorporated in 1999, is a wholly owned subsidiary of SIDBI (www.sidbi.in), the Apex Financial Institution in India for the MSME sector. Over the years, SVCL has set up and managed several Venture Capital Funds / AIFs, “Ubharte Sitaare Fund” is the eighth Fund set up and managed by SVCL.

If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

Related Posts

Business Excellence Awards 2024 organized by Corporate Connect

New Delhi (India), May 25: It is time to recognize and celebrate the extraordinary business innovation and entrepreneurship achievements. Corporate Connect is thrilled to announce the winners of its highly…

IB Group Emerges as Top 5 Poultry Company in Asia

New Delhi (India), May 25: In a resounding testament to its remarkable growth trajectory, IB Group, in collaboration with Aviagen®, proudly announces a significant milestone: the acquisition of 100,000 Grandparent Poultry (GP) stock in a…

You Missed

Dr. Krishna Kumar Mourya ji has selflessly served cows for 20 years and has set a world record by conducting post-mortems of more than 3000 cows

  • May 25, 2024
Dr. Krishna Kumar Mourya ji has selflessly served cows for 20 years and has set a world record by conducting post-mortems of more than 3000 cows

Flomic Global Logistics Achieves Landmark Milestone with Make in India Gondola Freight Wagons Shipment to Africa

  • May 25, 2024
Flomic Global Logistics Achieves Landmark Milestone with Make in India Gondola Freight Wagons Shipment to Africa

Morepen Labs Profit surges 143 percent while Revenue grows 20 percent in FY24, Dr. Morepen Medical Devices sales soar by 35 percent

  • May 25, 2024
Morepen Labs Profit surges 143 percent while Revenue grows 20 percent in FY24, Dr. Morepen Medical Devices sales soar by 35 percent

Testronix Instruments Announces Revolutionary Testing Solutions

  • May 24, 2024
Testronix Instruments Announces Revolutionary Testing Solutions

SEO on a Budget, This Free Toolkit is All You Need

  • May 24, 2024
SEO on a Budget, This Free Toolkit is All You Need

Orientation Training Programme for Arb-Med

  • May 24, 2024
Orientation Training Programme for Arb-Med